{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:58:16Z","timestamp":1793995096237,"version":"4.8.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["RC2DK118640"],"award-info":[{"award-number":["RC2DK118640"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["RC2DK122532"],"award-info":[{"award-number":["RC2DK122532"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:31:02Z","timestamp":1700267462000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Body Surface Area-Based Dosing of Infliximab is Superior to Standard Weight-Based Dosing in Children With Very Early Onset Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-6525","authenticated-orcid":false,"given":"Lorraine","family":"Stallard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Scarallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I.","family":"Benchimol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9624-3346","authenticated-orcid":false,"given":"Aleixo M.","family":"Muise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-3005","authenticated-orcid":false,"given":"Amanda","family":"Ricciuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2023.11.004_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.11.004_bib2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2023.11.004_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/2050640619847592","article-title":"Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study","volume":"7","author":"Bramuzzo","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastha.2023.11.004_bib4","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.gastha.2023.11.004_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2012.10.005","article-title":"Rational development and utilization of antibody-based therapeutic proteins in pediatrics","volume":"137","author":"Xu","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastha.2023.11.004_bib6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjad009","article-title":"A\u00a0model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases","volume":"17","author":"Kantasiripitak","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gastha.2023.11.004_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","volume":"28","author":"Dubinsky","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2023.11.004_bib8","doi-asserted-by":"crossref","first-page":"E586","DOI":"10.1152\/ajpendo.2001.281.3.E586","article-title":"Body surface area prediction in normal-weight and obese patients","volume":"281","author":"Livingston","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.gastha.2023.11.004_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MPG.0000000000001672","article-title":"Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience","volume":"66","author":"DeBruyn","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastha.2023.11.004_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.gastha.2023.11.004_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/MPG.0000000000001123","article-title":"Infliximab dosing strategies and predicted trough exposure in children with Crohn disease","volume":"62","author":"Frymoyer","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastha.2023.11.004_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.11.004_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.gastha.2023.11.004_bib14","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","article-title":"Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study","volume":"19","author":"Adedokun","year":"2013","journal-title":"Inflamm Bowel Dis"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:59:10Z","timestamp":1762646350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572323001796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572323001796"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.11.004","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body Surface Area-Based Dosing of Infliximab is Superior to Standard Weight-Based Dosing in Children With Very Early Onset Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}